Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-type p53

Molecular Carcinogenesis

Volumn 23, Issue 1, 1998, Pages 1-12

  Olivier, Magali ^a,c   Bautista, Silvia ^a   Vallès, Hélène ^b   Theillet, Charles ^a,b,c  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b Centre de Recherche   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Cell cycle checkpoints; DNA damage; p53

Indexed keywords

ANTIBIOTIC G 418; BLEOMYCIN; CELL NUCLEUS ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; ETOPOSIDE; MESYLIC ACID METHYL ESTER; MIMOSINE; MITOMYCIN C; PROTEIN P21; PROTEIN P53; TRITON X 100;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CHROMOSOME DAMAGE; CHROMOSOME REPLICATION; CONTROLLED STUDY; DNA CONTENT; GAMMA IRRADIATION; GENE ACTIVATION; GENE MUTATION; GENETIC DAMAGE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RESTRICTION SITE; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CELL CYCLE; CHROMOSOME ABERRATIONS; DNA DAMAGE; GAMMA RAYS; GENES, P53; HUMANS; MUTAGENS; MUTATION; ONCOGENE PROTEIN P21(RAS); OXIDATIVE STRESS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031710597     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199809)23:1<1::AID-MC1>3.0.CO;2-Q     Document Type: Article

References (66)

1. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6:12-19, 1996.
2. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell-cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
3. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
4. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318, 1993.
5. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
6. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature 362:849-852, 1993.
7. Clarke AR, Gledhill S, Hopper ML, Bird CC, Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9:1767-1773, 1994.
8. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
9. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993.
10. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
11. 1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994.
12. 1 checkpoint control. Cell 82:675-684, 1995.
13. Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell-cycle arrest compromised by p21 deficiency. Nature 377:552-557, 1995.
14. Rong L, Waga C, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537, 1994.
15. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386-388, 1995.
16. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92:8493-8497, 1995.
17. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221, 1992.
18. Hartwell L. Defects in a cell-cycle checkpoint may be responsible for genomic instability of cancer cells. Cell 71:543-546, 1992.
19. Livingstone LR, White A, Sprouse J, et al. Altered cell-cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992.
20. Lee JM, Bernstein A. p53 Mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90:5742-5746, 1993.
21. Tsang N, Nagasawa H, Li C, Little JB. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 10:2403-2408, 1995.
22. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53:4164-4168, 1993.
23. Fan S, Smith ML, Rivet DJ, 2nd, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654, 1995.
24. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996.
25. Servomaa K, Kiuru A, Grenman R, et-al. p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif 29:219-230, 1997.
26. Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification: Cancer Res 57:4368-4377, 1997.
27. Kallioniemi AH, Kallioniemi OP, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91:2156-2160, 1994.
28. Theillet C. p53 genes and solid tumors. Bull Cancer (Paris) 80:693-696, 1993.
29. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555, 1994.
30. Naryzhnyi S, Shevelev I, Krutiakov V. Effect of the antitumor antibiotic bleomycin on DNA polymerase activity. Biokhimiia 47:1212-1215, 1982.
31. Lopez-Larraza D, De-Luca J, Bianchi N. The kinetics of DNA damage by bleomycin in mammalian cells. Mutat Res 232:57-61, 1990.
32. 1 phase arrest and p53 function in human tumor cells. Cancer Res 55:1842-1846, 1995.
33. CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Oncol Res 8:317-323, 1996.
34. Moyret C, Madsen MW, Cooke J, Briand P, Theillet C. Gradual selection of a cellular clone presenting a mutation at codon 179 of the p53 gene during establishment of the immortalized human breast epithelial cell line HMT-3522. Exp Cell Res 215:380-385, 1994.
35. Weinert TA. Dual cell-cycle checkpoints sensitive to chromosome replication and DNA damage in the budding yeast Saccharomyces cerevisiae. Radiat Res 132:141-143, 1992.
36. 1 arrest in established human tumor cell lines. Oncogene 11:1885-1892, 1995.
37. 1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J Biol Chem 270:11033-11036, 1995.
38. Bae I, Smith ML, Sheikh MS, et al. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. Cancer Res 56:840-847, 1996.
39. Flaman JM, Waridel F, Estreicher A, et al. The human tumor suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12:813-818, 1996.
40. Fan S, El-Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res 54:5824-5830, 1994.
41. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540-2551, 1994.
42. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716, 1996.
43. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300, 1997.
44. Yount GL, Haas-Kogan DA, Vidair CA, et al. Cell-cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res 56:500-506, 1996.
45. Limoli CL, Kaplan MI, Phillips JW, Adair GM, Morgan WF. Differential induction of chromosomal instability by DNA strand-breaking agents. Cancer Res 57:4048-4056, 1997.
46. Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8:3447-3457, 1993.
47. Courjal F, Louason G, Speiser P, et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69:247-253, 1996.
48. Bullrich F, MacLachlan TK, Sang N, et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res 55:1199-1205, 1995.
49. Weinberg RA. The retinoblastoma protein and the cell cycle control. Cell 81:323-330, 1995.
50. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67-108, 1996.
51. Yuan ZM, Huang Y, Whang Y, et al. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 382:272-274, 1996.
52. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77:121-131, 1994.
53. Goga A, Liu X, Hambuch TM, et al. p53-dependent growth suppression by the c-Abl nuclear tyrosine kinase. Oncogene 11:791-799, 1995.
54. 1 arrest, p53, and Rb. Cancer Res 56:3645-3650, 1996.
55. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10:934-947, 1996.
56. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14:6264-6277, 1994.
57. Khanna KK, Lavin MF. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8:3307-3312, 1993.
58. 1 phase of the mammalian cell cycle. Exp Cell Res 186:332-339, 1990.
59. Fornace AJ, Jr. Mammalian genes induced by radiation: Activation of genes associated with growth control. Annu Rev Genet 26:507-526, 1992.
60. Zhan Q, Fan S, Smith ML, et al. Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation. DNA Cell Biol 15:805-815, 1996.
61. Liu ZG, Baskaran R, Lea-Chou ET, et al. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384:273-276, 1996.
62. Take Y, Kumano M, Teraoka H, Nishimura S, Okuyama A. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun 221:207-212, 1996.
63. Gioanni J, Le Francois D, Zanghellini E, et al. Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma. Br J Cancer 62:8-13, 1990.
64. 1/S boundary after irradiation. Oncogene 12:875-882, 1996.
65. 2M arrest following DNA damage in human colon cancer cell lines. Jpn J Cancer Res 88:39-43, 1997.
66. Wosikowski K, Regis JT, Robey RW, et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ 6:1395-1403, 1995.